Skip to main content
Toggle navigation
FR
EN
Drupal
Main navigation EN
About Crossject
Who we are
Governance
R&D
Our technology
ZENEO®: needle-free technology
Products under development
Our supply chain
Therapeutic areas
Epileptic seizure
Acute adrenal crisis
Anaphylactic shock
Severe asthma crisis
Migraines and cluster headaches
Opioid overdose
Rheumatoid arthritis
Main navigation 2 EN
Finances
Profile
Analyst coverage
Financial releases
News
Our news
Press releases
Careers
Working at Crossject
Contact
Search
Search
Enter the terms you wish to search for.
Home
Finances
Crossject signs a geographic extension of ZEPIZURE® commercialization agreement in Europe
Crossject signs a geographic extension of ZEPIZURE® commercialization agreement in Europe
Image
Date de parution
2024/05/02
PDF du document
2024-05- 02- Crossject_Press release_Extension_EN (2).pdf
185.47 KB
